---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-002944"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T06:17:17.199873+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aptose Q1 net loss $5.5M, cash only until end-May 2025; cites need for financing

## Summary
- Net loss of $5.5M for Q1 2025 vs. $9.6M a year ago; EPS loss $2.61.
- Cash and restricted cash $4.7M; company expects runway only through May 2025.
- TUSCANY trial: all six patients on 40 or 80 mg TUS+VEN+AZA achieved complete remissions.
- Common shares delisted from Nasdaq effective April 2, 2025 due to equity deficiency.
- Management pursuing financing and cost cuts to extend cash runway beyond May 2025.

## SEC filing metadata
- accession: 0001171843-25-002944
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184325002944/0001171843-25-002944-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184325002944/f8k_050825.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-002944
- JSON: https://secwatch.observer/filing/0001171843-25-002944.json
- Plain text: https://secwatch.observer/filing/0001171843-25-002944.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.